Infant Bacterial Therapeutics AB (publ)
SSE:IBT-B.ST
93.4 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.077 | 0.012 | 0 | 0 | 0 | 0 | 0.238 | 0.162 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0.816 | 0.816 | 0 | 0.811 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.077 | 0.012 | 0 | 0 | -0.816 | -0.816 | 0.238 | -0.649 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 1 | 0 | 0 | 0 | 0 | 1 | -4.006 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 123.257 | 65.82 | 44.672 | 72.23 | 47.2 | 39.417 | 36.379 | 40.795 | 17.974 | 6.592 | 0.229 | 0 |
| General & Administrative Expenses
| 13.511 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.543 | 2.6 | 0 | 0 | 0 |
| SG&A
| 13.511 | 1.017 | 1.115 | 1.136 | 1.235 | 1.086 | 0.957 | -2.543 | 2.6 | 0 | 0 | 0 |
| Other Expenses
| 0 | -0.012 | -0.094 | -0.312 | 0 | 0 | 0 | -2.543 | 0.041 | 0 | 0 | -0.002 |
| Operating Expenses
| 136.768 | 65.808 | 44.578 | 71.918 | 47.2 | 39.417 | 36.379 | 38.252 | 20.615 | 6.592 | 0 | -0.002 |
| Operating Income
| -136.768 | -65.808 | -44.578 | -71.918 | -47.2 | -39.417 | -36.141 | -38.09 | -20.615 | -6.592 | -0.229 | -0.002 |
| Operating Income Ratio
| -1,776.208 | -5,484 | 0 | 0 | 0 | 0 | -151.853 | -235.123 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 13.7 | 0.357 | -0.413 | -0.089 | 0.88 | -1.19 | -0.015 | -0.016 | -0.009 | -0.155 | 0.229 | -0.002 |
| Income Before Tax
| -123.068 | -65.451 | -44.991 | -72.007 | -46.32 | -40.607 | -36.156 | -38.106 | -20.624 | -6.747 | 0 | -0.002 |
| Income Before Tax Ratio
| -1,598.286 | -5,454.25 | 0 | 0 | 0 | 0 | -151.916 | -235.222 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -134.617 | -0.357 | 0.413 | 0.303 | 0.725 | 0.327 | 0 | 0 | -20.615 | 0 | 0 | 0 |
| Net Income
| -123.068 | -65.094 | -45.404 | -72.31 | -47.045 | -40.607 | -36.156 | -38.106 | -20.624 | -6.747 | 0 | -0.002 |
| Net Income Ratio
| -1,598.286 | -5,424.5 | 0 | 0 | 0 | 0 | -151.916 | -235.222 | 0 | 0 | 0 | 0 |
| EPS
| -9.95 | -5.8 | -4.04 | -6.44 | -4.19 | -3.76 | -6.46 | -7.54 | -10.06 | -2.02 | 0 | -0.001 |
| EPS Diluted
| -9.95 | -5.8 | -4.04 | -6.44 | -4.19 | -3.76 | -6.46 | -7.54 | -10.06 | -2.02 | 0 | -0.001 |
| EBITDA
| -136.768 | -64.342 | -43.762 | -70.888 | -44.779 | -38.274 | -35.325 | -37.279 | -20.615 | -6.591 | 0.229 | -0.002 |
| EBITDA Ratio
| -1,776.208 | -5,361.833 | 0 | 0 | 0 | 0 | -148.424 | -230.117 | 0 | 0 | 0 | 0 |